 Mohan
Philip, Ph.D., MBA
Mohan Philip, Ph.D., MBA, is one of the founders of Immunotope, Inc.,
and served as the Chief Operating Officer. Prior to forming Immunotope,
Dr. Philip was Chief Scientific Officer of RHeoGene LLC (Charlottesville
VA) beginning with its formation in July 1999. Prior to RHeoGene, he was
Vice President for Gene Therapy Research at Argonex Inc., one of the two
parent companies of RHeoGene.
Prior to Argonex, Dr. Philip was the head of Vector Development and Oncology
Department at Rhone Poulenc Rorer Gencell. Dr. Philip joined RPR Gencell
in 1993 and had a key role in several gene therapy projects. He developed
pMP6/Avectin vectors that were used in three approved clinical trials.
In addition to overseeing vector development activities for p53, suicide/immunotherapy
and antiangiogenesis projects, he also initiated the vector-targeting
program at Gencell.
From 1988 to 1993, Dr. Philip was a research scientist at Neurex Corporation,
where he had a leadership role in cloning neuron specific calcium channels.
He was also an Associate Professor of Research in Internal Medicine at
the University of Virginia, Charlottesville. Dr. Philip received his Ph.D.
from the Indian Institute of Science, Bangalore, India, in Biological
Sciences and did his postdoctoral work with Prof. D. Brutlag in the Biochemistry
Department at Stanford University.
|
|
